MotixafortideCXCR4 antagonist
Motixafortide helps move blood-forming stem cells from bone marrow into the bloodstream. The clinical goal is to collect enough cells for a planned transplant, not to provide general rejuvenation.
What is Motixafortide?
Motixafortide is a CXCR4 antagonist used with G-CSF to mobilise blood-forming stem cells for collection before autologous transplantation in multiple myeloma. Collection is a preparatory step in a larger treatment pathway. 1 2
How it works
Blocking CXCR4 disrupts signals that retain stem cells in bone marrow, allowing more of them to enter circulating blood for apheresis collection. 1 2
Effects studied
Stem-cell collection
GENESIS evaluated reaching a target stem-cell collection yield. Successful mobilisation is not itself a measure of cancer cure or rejuvenation.
Evidence: Randomised mobilisation trial. 1
What does the evidence show?
Randomised stem-cell mobilisation trial
Releasing cells from their marrow niche
The CXCR4 receptor helps keep blood-forming stem cells in the bone marrow through signalling with CXCL12. Motixafortide blocks this interaction. More cells can then enter the circulation, where an apheresis procedure can collect them for later use.
Why this matters in myeloma care
Some people with multiple myeloma undergo an autologous transplant, which uses their own previously collected stem cells after intensive treatment. Collection can be a bottleneck. A medicine that improves mobilisation may reduce the number of collection procedures or the need for an alternative mobilisation strategy.
What the trial measured
The GENESIS trial compared motixafortide plus granulocyte colony-stimulating factor with the mobilisation regimen without motixafortide. Its main outcomes concerned reaching a target stem-cell yield. Those results do not show that motixafortide cures myeloma, regenerates organs or improves longevity. 1
The collection benefit has treatment burdens
Injection-site effects and hypersensitivity reactions are important practical considerations. Mobilisation, collection and transplantation are separate steps, with different eligibility requirements and risks. The retained label describes the specific product; local approval and current transplant protocols still require verification. 2
Safety & status
Injection-site reactions and hypersensitivity can occur. Administration and collection take place within a specialist transplant programme. 2
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Does it directly treat the myeloma?
Its role here is helping collect stem cells for transplantation, not directly establishing cancer control. 1
Why is it combined with G-CSF?
The studied mobilisation regimen uses both agents; its findings should be attributed to that regimen rather than motixafortide alone. 1
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.